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Background. Excess adiposity and premature adrenarche (PA) are risk factors for the development of polycystic ovary syndrome
(PCOS). Methods. Girls with slowly progressive precocious breast development, who were overweight and had PA (SPPOPA, 6.2–
8.2 years, n = 5), overweight PA (6.6–10.8 years, n = 7), and overweight premenarcheal controls (OW-PUB, 10.6–12.8 years,
n = 8) underwent hormonal sleep testing and GnRH agonist (GnRHag) and ACTH tests. Results. Despite an insigniﬁcant sleep-
related increase in LH and prepubertal baseline hormone levels, SPPOPA peak LH and estradiol responses to GnRHag were
intermediatebetweenthoseofPAandOW-PUB,theLHbeingsigniﬁcantlydiﬀerentfromboth.Conclusions.GnRHagtestsindicate
that SPPOPA is a slowly progressive form of true puberty with blunted LH dynamics. These results argue against the prepubertal
hyperandrogenism of excess adiposity or PA enhancing LH secretion or causing ovarian hyperandrogenism prior to menarche.
Excess adiposity may contribute to both the early onset and slow progression of puberty.
1.Introduction
We have characterized a variant group of sexually precocious
girls who presented diagnostic challenges that provided
an opportunity to test hypotheses about pubertal patho-
physiology. They met current criteria for sexual precocity,
with breast and pubic hair development before 8 years of
age [1–3]. However, they diﬀered from girls with typical
central precocious puberty (also termed complete, true, or
gonadotropin-dependent premature puberty) because they
had slowly progressive precocious breast development [4–6],
were overweight, and had premature adrenarche (SPPOPA).
Their early morning LH serum levels were also persistently
prepubertal during the initial observation period. About
one-third of girls with central precocity are overweight [7],
about half have premature adrenarche (PA) [6], although it
causes pseudoprecocity independently of true puberty [8],
and only about 10% have early morning LH levels in the
prepubertal range [9]. Thus, our SPPOPA group presented
an uncommon, but not rare, combination of ﬁndings.
Their peripubertaladiposity and hyperandrogenismsug-
gested that they were at risk of developing polycystic ovary
syndrome (PCOS), a hyperandrogenic anovulation disorder
that is often accompanied by obesity [10]. Obesity poten-
tially predisposes to the development of PCOS by causing
p r e m e n a r c h e a lL He x c e s st h a ti sm e d i a t e db yp e r i p u b e r t a l
hyperandrogenemia [11–13]. PA, a mild form of adrenal
hyperandrogenism, potentially poses increased risk for the
development of PCOS, particularly in obese and African-
American or Hispanic girls [10, 14, 15].
The diagnostic challenge was to determine whether
SPPOPA girls had early activation of the neuroendocrine-
gonadal axis that ordinary testing failed to capture, whether
their thelarche was due to adiposity-related peripheral
estrogen formation [16], or whether they simply had pseu-
dothelarche due to adipomastia. If they had adipomastia or
estrogen excess of peripheral origin, one would expect LH
dynamics to be suppressed, that is, no greater than the pre-
pubertal pattern expected in isolated PA. If they had central
precocity related to PA predisposing to PCOS, it might be
expected that their LH would be higher than that of controls
in a similarly early stage of puberty because of peripubertal
hyperandrogenemia [11–13]; it might also be expected that
inherent ovarian dysfunction would be apparent in early2 International Journal of Pediatric Endocrinology
puberty [17]. Thus, deﬁnition of their pathophysiology was
potentially instructive for understanding the developmental
origins of PCOS [10, 18]. To test these possibilities, we
surveyed their hypothalamic-pituitary-ovarian function by
analyzing gonadotropin secretion during sleep, since the
ﬁrst hormonal changes of puberty begin then [19]; by
assessing their gonadotropin and sex steroid responses to a
GnRH agonist (GnRHag) test; and by testing their adrenal
androgenic sensitivity to ACTH. The results indicate that
these girls indeed have a slowly progressive form of central
precocious puberty, with blunting of their early pubertal
LH production in spite of peripubertal hyperandrogenemia;
these results may be related to our recent ﬁndings in
healthygirls that excess adiposity subtlyblunts gonadotropin
secretion during the early stages of puberty [20].
2.SubjectsandMethods
2.1. Subjects. SPPOPA girls (4 African-American, 1 His-
panic) presented with premature breast and pubic hair
development; thelarche had occurred at 5–7.5 years of
age, was predominantly at stage 3 at admission, and was
uniformly preceded by pubarche, by a median of 0.5
years. Preadmission early morning blood sampling showed
that these girls’ premature pubarche was accompanied
by adrenarcheal levels of dehydroepiandrosterone sulfate
(DHEAS) and testosterone; however, despite their obvious
thelarche, they had prepubertal gonadotropin and estradiol
levels. PA girls (3 African-American, 4 Caucasian) presented
with pubarche that began at 3–8 years of age, and 6/7
had above average height velocity, high bone age/height
age ratio, obesity, acanthosis nigricans, or high DHEAS for
pubic hair stage, which are sometimes considered to be
signs of “exaggerated adrenarche” [10, 21, 22], but none
had breast development. Healthy overweight pubertal (OW-
PUB, 7 African-American, 1 Hispanic) female volunteers
were recruited by advertisement and were premenarcheal
and predominantly breast stage 3, as previously described
[20]. For the purposes of this study “overweight” was
used in the sense of “excessive” and deﬁned as body mass
index (BMI) >85th percentile and, thus, included obese
subjects (≥95th percentile) [23]. Patients were followed for
0.4 years or more (median 2.0 ± 0.5). Congenital adrenal
hyperplasia was excluded from all by ACTH-testing (see
below). These studies were approved by the University of
Chicago Institutional Review Board and were performed
after obtaining assent of the girls and consent of the parents.
2.2. Study Protocol. Subjects were admitted to the University
of Chicago General Clinical Research Center between 2001
and 2005 and studied by a previously reported protocol
(Table 1)[ 20]. At 1900hr, a hormonal sleep test was begun
with sampling by continuous blood withdrawal until 2 or
more hr after sleep onset, as assessed by observation, with
the exception of 3 subjects in the PA group and 1 in
the SPPOPA group whose sleep studies lasted 0.3–1.3hr.
LH was measured every 20min, FSH and estradiol in 2-
hr pools. At 0800hr the next morning, baseline fasting
blood samples were obtained. An oral glucose tolerance
test was then performed according to American Diabetes
Association guidelines: after a fasting sample was obtained,
subjects were given glucose in solution (Glucola), 1.75 grams
per kg body weight up to a maximum of 75 grams, with
repeat sampling at 2 hours for serum glucose and insulin.
Concurrently, blood was sampled every 15min to determine
baseline mean gonadotropin levels. Then a pelvic ultra-
sound examination was performed. At 1200hr, low-dose
dexamethasone (0.25mg/m2)w a sg i v e no r a l l yt oa t t e n u a t e
spontaneous adrenocortical secretion during the subsequent
ACTH test. At 1600hr, basal sampling was performed, then
low-dose ACTH1-24 (1.0mcg/1.7m2 IV) was administered,
and blood was sampled at 15, 30, and 60min for steroids.
At 1800hr, GnRHag (leuprolide acetate) (10mcg/kg SC) was
given, after collecting blood every 15min for 1hr for basal
gonadotropins, and gonadotropins were sampled for 4.0hr.
Post-GnRHag steroidogenic responses were assessed at 18hr,
thendexamethasonewasreadministeredandsteroidsfurther
assessed at 20–24hr (1400–1800hr).
2.3. Laboratory and Procedural Methods. As previously
reported, serum LH and FSH were measured by immuno-
ﬂuorometric assays (Delphia, Wallach, Finland); total testos-
terone and cortisol by Diagnostic Products Corporation
radioimmunoassay kits (Los Angeles, CA); dehydroepian-
drosterone sulfate (DHEAS) by Diagnostic Systems Labora-
tory kits (Webster, TX); estradiol by Pantex immunoassay
kit (Santa Monica, CA); free testosterone and sex hormone
binding globulin binding capacity were calculated from
a competitive protein binding assay [20]. Postchromato-
graphic radioimmunoassays were used for steroid inter-
mediates (17-hydroxyprogesterone, androstenedione, 11-
deoxycortisol,17-hydroxypregnenolone,andDHEA).Serum
insulin was initially assayed by a double-antibody RIA; the
method was changed to Immulite assay in 2004, and the data
are expressed in terms of the latter assay [24]. Each hormone
on a study subject was assayed simultaneously. Values below
the limits of assay sensitivity were set to this limit for
statistical analysis, as previously reported. Plasma glucose
was measured using a glucose analyzer (YSI Model 2300
STAT; Yellow Springs Instruments, Yellow Springs, OH).
Insulin resistance was approximated by homeostatic model
assessment (HOMA) according to the equation HOMA=
[fasting plasma insulin (mU/L)×fasting plasma glucose
(mmol/L)]/22.5 [25]. Real-time pelvic ultrasound imaging
was performed in the Pediatric Radiology Department by
the abdominal route using an Acuson Sequoia with a 4Mhz
transducer (Acuson, Mountainview, CA) according to the
manufacturer’s speciﬁcations using standard algorithms and
a phantom probe for periodic calibration [26]. There was no
signiﬁcantvariationbetweenreadingsbythetworadiologists
whoperformedthesestudies.Ovarianvolumewascalculated
according to the formula for ellipsoid bodies. Bone age was
determined by a modiﬁcation of the Greulich-Pyle method
[27], and adult height was predicted by the Bayley-Pinneau
method [28]. BMI percentiles were obtained from a national
database [29] and height velocity norms from Tanner and
Davies [30].International Journal of Pediatric Endocrinology 3
Table 1: Outline of study protocol.
Day Clocktime Procedure
Day 1 1900 Overnight hormonal sleep test
Day 2 0800 Baseline sampling begins
Oral glucose tolerance test
Pelvic ultrasound examination
1200 Dexamethasone 0.25mg/m2 PO
1600 Basal sample for steroids
1601 ACTH1-24 (1.0mcg/m2 IV) test begins
1700 Basal GnRHag test LH&FSH sampling begins
1800 GnRHag test (leuprolide 10mcg/m2 SC) test begins
Day 3 1200 Post-GnRHag 18hr sampling
1201 Dexamethasone 0.25mg/m2 PO
1400 Post-GnRHag sampling resumes (20hr)
1800 GnRHag test sampling ends (24hr)
2.4. Data Analyses. Group data, including hormonal
responses log-transformed as necessary for data normali-
zation, were compared by one-way ANOVA (comparisons
among groups) with subsequent pairwise comparisons
performed by Tukey’s method (sleep tests) or paired and
unpaired Student’s t-tests (baseline hormones), Fisher’s
exact test (for categorical variables), two-way repeated
measures ANOVA (GnRHag test), and paired and unpaired
Student’s t-tests (2-sample comparisons). Primary outcome
variableswerethecomparisonsofSPPOPAtoPAandtoOW-
PUB for sleep and GnRHag tests. Correction for multiple
comparisons was carried out by Fisher’s protected least
signiﬁcant diﬀerences post hoc testing. Results are expressed
as mean±SEM, unless otherwise stated. Two-tailed P-values
<. 05 were considered signiﬁcant.
3. Results
3.1. Clinical Characteristics. Baseline BMI percentile and
pubic hair stage were similar in the three study groups;
SPPOPA and OW-PUB girls had similar breast stage and
bone age (Table 2). Height velocities of all patients at entry
were above average for age. SPPOPA breast development
progressed slowly (averaging one stage yearly), and the
bone age/height age ratio (1.12 ± 0.0 5 )a n dp r e d i c t e da d u l t
height (160.4 ± 2.7cm) did not change signiﬁcantly during
untreated follow-up. Menarche was later documented at 9.4
and 10.5 years in two SPPOPA girls, which was at most
mildly earlier than the 5th percentile for OW girls (10.1yr,
95%conﬁdenceinterval9.5–10.7yr)[2,3],atnormalheights
of 159.1 and 152.9cm, respectively. Neither of these girls
had a remarkable premenarcheal hormonal pattern nor an
elevated perimenarcheal free testosterone level. In two PA
girls, menarche was later documented at 11.1 and 13.9 years
of age at heights of 148.1 and 156.7cm, respectively. In
the latter, free testosterone levels were found to be high
(15pg/mL) shortly after menarche, BMI was 93rd percentile.
Her course was remarkable for her mother having a history
of PCOS, and over the subsequent year, she developed
persistent hyperandrogenemia, acne, and irregular cycles,
indicating that she had developed PCOS [31].
SPPOPAHOMAindexwasintermediatebetweenPAand
OW-PUB (Table 2), with one subject having insulin resis-
tance (HOMA 10.8) in association with impaired glucose
tolerance. However, impaired glucose tolerance prevalence
was not signiﬁcantly diﬀerent among groups.
Early morning baseline hormone testing (Table 3)
showed that all groups had similarly adrenarcheal DHEAS,
androstenedione, and free testosterone levels, while SPPOPA
and PA both had similarly prepubertal gonadotropin levels
that diﬀered signiﬁcantly from those of OW-PUB girls.
However, SPPOPA had baseline ovarian volume (Table 2)
a n de s t r a d i o ll e v e l s( Table 3) intermediate between PA and
OW-PUB. Baseline sex hormone binding globulin, 17-
hydroxyprogesterone, and progesterone levels were similar
among groups.
3.2. Sleep Test. SPPOPA resembled PA in having prepubertal
evening wake LH and FSH levels, which were signiﬁcantly
lower than in OW-PUB (Table 4). Wake estradiol levels of
two SPPOPA girls exceeded the prepubertal range, so the
mean for SPPOPA girls was intermediate between PA and
OW-PUB girls, who diﬀered signiﬁcantly.
Peak sleep LH and estradiol of all but one SPPOPA and
one PA girl were in the prepubertal range, as were all their
FSH peaks (Table 4). The peak sleep LH of PA and OW-
PUB girls diﬀered signiﬁcantly, and that of SPPOPA was
intermediate. None of the groups had a signiﬁcant sleep-
related LH rise: mean sleep LH in PA was 0.13 ± 0.1, in
SPPOPA 0.15 ± 0.0 7a n di nO W - P U B0 .68 ± 0.35U/L. Sleep
estradiol levels of both SPPOPA and PA were signiﬁcantly
lower than in OW-PUB (Table 4).
3.3. GnRHag Test. Despite their prepubertal gonadotropin
levels at baseline and asleep, SPPOPA girls had LH responses
to GnRHag testing that were both signiﬁcantly greater than
those of PA girls and less than those of OW-PUB girls by4 International Journal of Pediatric Endocrinology
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Table 4: Study group wake and sleep gonadotropin and estradiol levels. Observed range for each study group is shown, as is 5th–95th
percentile reference range of healthy prepubertal volunteers [20].
GROUP LH (U/L) FSH (U/L) Estradiol (pg/mL)
Mean Wake Peak Sleep Mean Wake Peak Sleep Mean Wake Peak Sleep
PA (n = 7)
Mean 0.16a 0.50a 1.3a 2.1 7.6a 5.5a
SEM 0.01 0.22 0.13 0.56 0.88 0.5
Range ≤0.15–0.20 ≤0.15–1.8 0.85–1.7 1.0–5.2 ≤5.0–10.5 ≤5.0–8.0
SPPOPA (n = 5)
Mean 0.15a 0.68 1.4a 2.0 13.1 7.9a
SEM 0.00 0.17 0.20 0.41 3.1 1.3
Range ≤0.15–0.17 ≤0.15–1.2 0.72–1.9 1.1–3.0 5.5–23.0 ≤5.0–12.0
OW-PUB (n = 8)
Mean 2.6 5.3 4.0 4.4 25.5 28.9
SEM 0.89 1.7 0.87 0.88 4.4 7.2
Range ≤0.15– 6.9 ≤0.15–13.5 0.68–7.2 0.60–6.8 10.5–43.7 7.0–63.0
Prepubertal (n = 20)
Reference Range ≤0.15 0.15–0.85 0.40–1.6 0.5–3.0 ≤5.0–16.0 ≤5.0–9.0
P-values versus OW-PUB: a<.05, b<.01.
ANOVA (Figure 1, Table 5). Their LH peaks were likewise
signiﬁcantly diﬀerent (P<. 05); that of PA was 3.1 ± 0.8,
SPPOPA 10.0 ± 2.9, and OW-PUB 54.2 ± 14.6U/L.TheLH
response at 4hr was the best discriminant among groups;
that of each SPPOPA case was >4.0IU/L, which is the 90th
percentile for prepubertal controls, in whom the only higher
values occurred in ≥8.4 year-olds. In contrast, SPPOPA and
PA had similar FSH responses to GnRHag that diﬀered
signiﬁcantly from OW-PUB in being less-sustained. The
LH/FSH ratio in response to GnRHag rose >1.0 in only 20%
ofSPPOPA,comparedto75%ofOW-PUB,butin60%itwas
above that of PA girls.
SPPOPA estradiol responses were intermediate between
those of PA and OW-PUB girls, which diﬀered signiﬁcantly
(Figure 1). The modal time of estradiol peak responses
was not signiﬁcantly diﬀerent among groups but tended
to be earliest within the 18–24hr period in the PA group
and latest within the OW-PUB group. SPPOPA estradiol
peak responses (56.1 ± 13.2pg/mL) occurred 18–22hr post-
GnRHag and were between those of PA (33.0 ± 5.8pg/mL)
and those of OW-PUB (148 ± 36pg/mL), which diﬀered
signiﬁcantly (Table 5).
SPPOPA and PA had similar 17-hydroxyprogesterone
responses to GnRHag, and both were signiﬁcantly less than
those of OW-PUB (Table 5). The SPPOPA post-GnRHag
testosterone 22-hr level was pubertal, signiﬁcantly greater
than that of PA, while that of androstenedione was interme-
diate between PA and OW-PUB, which diﬀered signiﬁcantly.
The responses of progesterone and DHEA to GnRHag did
not diﬀer among groups.
3.4. ACTH Test. SPPOPA and PA had similarly adrenarcheal
responses to ACTH that were elevated for age and similar to
thoseofOW-PUB,thoughonaverageabovethem(Figure 2).
Steroidogenic response peaks occurred within 30 minutes
and were otherwise unremarkable.
4. Discussion
SPPOPA girls present an infrequent, but not rare, diagnostic
challenge. The clinical presentation with premature breast
and pubic hair development and course of these cases was
typical of the slowly progressive form of central precocity
[4, 5]. However, while early morning hormone sampling in
these SPPOPA girls showed premature adrenarche, it did not
show pubertal gonadotropin levels. Two mechanisms were
considered as possibly underlying this clinical picture, aside
from the possibility of the pseudothelarche of obesity. The
ﬁrst was that outpatient testing failed to detect early puberty,
thealternatewasthatthecombinationofprematureadrenar-
che and excessive adiposity caused premature thelarche via
the enhanced peripheral estrogen formation of obesity. We
also tested the hypotheses that if they were indeed pubertal,
their peripubertal hyperandrogenism would predispose to
increased LH levels as an early manifestation of PCOS [11–
13] and premature adrenarche would predispose them to a
unique ovarian androgenic response to GnRHag [17].
Consistent withtheﬁrstmechanistic possibility, SPPOPA
girls had responses to GnRHag testing that were signiﬁcantly
greater than those of PA girls, and thus had undergone
pubertal gonadotrope activation. While diagnostic criteria
for this test are not well established, their LH levels 4hr post-
GnRHag were all >4.0U/L, which is in the midst of ranges
of cut-oﬀs proposed for diverse assays in diagnosing central
precocity by GnRH testing (3.3–5.0U/L) [1].
Adrenal androgen baseline levels and responses to ACTH
of the SPPOPA and PA girls were elevated for age and
tended to be higher than those of premenarcheal pubertal
volunteers. SPPOPA girls did not have higher LH param-
eters than comparably overweight early pubertal controls,
as might be expected if the hypothesis were true that
peripubertal hyperandrogenism predisposes to elevated LH
secretion of PCOS commencing during stage 3 of pubertyInternational Journal of Pediatric Endocrinology 7
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Figure 1: Baseline and peak LH, FSH, and estradiol (E2) responses to GnRHag testing. SPPOPA girls had greater LH responses to GnRHag
testing than PA girls and FSH and E2 responses intermediate between those of PA and OW-PUB girls. Prepubertal (PRE) reference range
shown for comparison [20]. Note logarithmic axes. Error bars depict SEM.
[11–13]. Indeed, LH was lower, as discussed below. However,
our SPPOPA group was not hyperandrogenic for their
stage of pubertal maturation, so it remains unclear at
what point in pubertal development, and at what level,
hyperandrogenemiabecomescapableofstimulatingpulsatile
LHsecretion,asitdoesaftermenarche[32,33].Additionally,
SPPOPA girls had no evidence of the pubertal ovarian
DHEA hyperresponsiveness that has been reported to follow
presentation with PA and has been suspected of indicating
riskfordevelopingPCOS[17];thediﬀerenceinﬁndingsmay
be explicable by the diﬀerence in BMI status of our PA popu-
lation or our study design in which low-dose dexamethasone
was used to eliminate artifacts arising from coincidental
adrenal secretion. However, our limited long-term follow-upInternational Journal of Pediatric Endocrinology 9
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Figure 2: Steroid intermediate basal levels and responses to ACTH-stimulation. Although SPPOPA and PA girls had DHEA basal levels and
responses and 17-hydroxypregneneolone responses elevated for age, the three groups did not diﬀer in their basal levels or adrenal responses
toACTH.Prepubertal(PRE)referencerangeshownforcomparison[20].Notediﬀerentscalesforbasalandstimulatedsteroidintermediates.
Error bars depict SEM. Abbreviations not otherwise used: 17-PREG (17-hydroxypregnenolone); Cmpd S (11-deoxycortisol).
revealed one PA girl to develop PCOS after menarche; there
was nothing in her study that distinguished her from the
others in the PA group except the maternal history of PCOS.
The slowly progressive form of central precocious
puberty generally diﬀers from classical (rapidly progressive)
central precocity in its lesser activation of hypothalamic
GnRH secretion [34]. Thus, these patients ordinarily have
lower LH peaks and LH/FSH ratios in response to GnRH
[6, 34, 35], fewer and lower LH pulses during sleep [6], and
tendtobelessestrogenized[5,35].Clinically,pubertaltempo
is not accelerated [4, 5], the age of menarche is, on average,
within normal limits [6, 35], and adult height potential is
preserved without treatment [35].
Although the SPPOPA group was typical of slowly
progressive precocity in these general ways, their LH
dynamics were signiﬁcantly attenuated for their level of
pubertal maturation in comparison to ordinary OW early
pubertal controls. Wake gonadotropins and LH responses
to GnRHag were signiﬁcantly lower than those of the
comparably overweight pubertal controls. These overweight
controls themselves had a blunted sleep-related rise in LH
pulse amplitude and pulse frequency relative to normal-
BMI controls; however, they had responses to GnRHag like
those of normal-weight pubertal girls [20]. The data are
compatible with the possibility that early pubertal girls are
particularly sensitive to the gonadotropin-suppressive eﬀects
of obesity.
Evidence is accumulating that excess adiposity reduces
LH production. LH levels and pulse amplitude are low
in morbidly obese men with hypogonadism [36] and low
in eumenorrheic obese women with anovulatory cycles
[37]; the LH responses to GnRH of obese women increase
with weight loss [38]; and LH levels, pulse amplitude; and
response to GnRH are lower in obese than in nonobese
PCOS [39]. The lower LH of obese PCOS women is partly
attributable to increased LH clearance [40]. The available
longitudinal data are compatible with excess adiposity after
the onset of puberty slowing pubertal tempo in girls, though
less so than prepubertal adiposity advances puberty onset
[41–43]. Thus, these considerations raise the possibility that
the excess adiposity of SPPOPA aggravates the relatively
low LH production of slowly progressive precocity and
contributes to the slow progression.
Since there is considerable evidence that excess adiposity
advances the onset of puberty [2, 3, 44], it is possible
that it paradoxically contributes to both the early onset
of puberty in SPPOPA as well as to its slow progression
thereafter. We speculate that overweight may be a factor in
the precocity of girls in whom, like these, onset of puberty
is only mildly premature; many sexually precocious girls in
this 6–8 year age range do not require treatment to preserve
height potential [1].
The limitations of this study should be kept in mind.
It is descriptive and associative and should be considered
exploratory. Furthermore, while the SPPOPA presentation is
not rare, it is uncommon, and our group was small. Because
our study was designed as a survey of the many aspects of
puberty potentially disturbed in these young girls, our sleep
data are sparse. In addition, we have not been able to obtain
follow-up into the postmenarcheal stage of development in
most. In spite of these limitations, our data indicate that
mild peripubertal hyperandrogenism and excess adiposity
do not predispose to elevated LH secretion during early
puberty before menarche and are indeed compatible with
the possibility of a suppressive eﬀect of excess adiposity on
circulating LH during puberty that deserves further study.10 International Journal of Pediatric Endocrinology
5. Conclusion
In summary, we demonstrate that sleep-related gonadot-
ropin production and LH responses to GnRH agonist testing
are blunted in girls with slowly progressive sexual precocity
who are overweight and have premature adrenarche. These
studies indicate that SPPOPA is a slowly progressive form
of true puberty. In spite of maturational indices similar to
OW-PUB,SPPOPAhadlowerLHresponsestoGnRHag.The
dataargueagainstthehypothesesthattheprepubertalhyper-
androgenism of excess adiposity or premature adrenarche
enhance LH secretion or cause ovarian hyperandrogenism
prior to menarche, although they seem to be modest risk
factors for PCOS thereafter. These data are also compatible
with the possibility that early pubertal girls are particularly
sensitive to the gonadotropin-suppressive eﬀects of excess
fat mass, although obesity predisposes to the early onset of
puberty.
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